Novel antifungal shows early promise against Candida auris

  11 April 2019

Biotechnology company Scynexis, Inc., is reporting early but promising results from a phase 3 trial of a novel drug for treating invasive Candida aurisinfections.

The company will present the results from the first two case studies in the CARES trial at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam. The single-arm trial is evaluating the efficacy and safety of oral ibrexafungerp in patients with candidiasis caused by C auris, a multidrug-resistant fungus that has triggered deadly outbreaks in healthcare facilities around the world, with mortality rates as high as 60%.

Further reading: CIDRAP
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!